Kymera Therapeutics’ (KYMR) “Outperform” Rating Reaffirmed at Leerink Partners

Leerink Partners restated their outperform rating on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research report sent to investors on Monday, Marketbeat Ratings reports. The brokerage currently has a $60.00 price target on the stock.

A number of other analysts also recently issued reports on KYMR. HC Wainwright reiterated a buy rating and issued a $46.00 price target on shares of Kymera Therapeutics in a report on Monday, June 17th. Oppenheimer reaffirmed an outperform rating and issued a $52.00 target price on shares of Kymera Therapeutics in a report on Wednesday, July 10th. Wells Fargo & Company increased their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the company an equal weight rating in a research note on Monday, August 12th. B. Riley lifted their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a neutral rating in a research note on Tuesday, July 9th. Finally, Wolfe Research raised shares of Kymera Therapeutics from a peer perform rating to an outperform rating and set a $65.00 target price for the company in a report on Monday, August 26th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $48.67.

Kymera Therapeutics Stock Down 0.1 %

NASDAQ:KYMR opened at $44.72 on Monday. The stock has a market cap of $2.74 billion, a PE ratio of -17.82 and a beta of 2.22. The business’s 50-day simple moving average is $43.93 and its two-hundred day simple moving average is $38.89. Kymera Therapeutics has a 52 week low of $9.60 and a 52 week high of $50.19.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.10. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The business had revenue of $25.60 million during the quarter, compared to the consensus estimate of $12.55 million. During the same period in the prior year, the company posted ($0.67) EPS. The firm’s revenue for the quarter was up 55.2% compared to the same quarter last year. Sell-side analysts anticipate that Kymera Therapeutics will post -2.86 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Jared Gollob sold 23,145 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total value of $1,060,272.45. Following the completion of the sale, the insider now owns 95,470 shares in the company, valued at approximately $4,373,480.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jared Gollob sold 23,145 shares of Kymera Therapeutics stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total value of $1,060,272.45. Following the sale, the insider now owns 95,470 shares of the company’s stock, valued at $4,373,480.70. The disclosure for this sale can be found here. Insiders have sold 482,105 shares of company stock worth $18,651,584 over the last quarter. Insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its position in Kymera Therapeutics by 5.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,335,712 shares of the company’s stock valued at $135,848,000 after buying an additional 278,287 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Kymera Therapeutics by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company’s stock valued at $101,778,000 after purchasing an additional 72,351 shares during the period. Campbell & CO Investment Adviser LLC bought a new position in Kymera Therapeutics in the fourth quarter worth approximately $792,000. BVF Inc. IL grew its stake in Kymera Therapeutics by 8.9% in the fourth quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock worth $131,419,000 after purchasing an additional 422,797 shares in the last quarter. Finally, Jennison Associates LLC purchased a new position in Kymera Therapeutics during the 1st quarter worth $17,122,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.